This is an observational, retrospective pharmacovigilance study based on reports registered and transmitted in VigiBaseĀ®, the WHO's international database. This study includes all reports identified as exposure to an ICI and suspect of inducing adverse drug reaction. The aim of the study is to characterize immune-related adverse reactions associated with immune-checkpoint inhibitors, particularly their time-to-onset, co-occurence, factors associate with their over-report and fatality.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Factors associated with an increased rate of fatality among reports with an immune-related adverse event (irAE).
Timeframe: any report prior to january 2023